Abstracts tagged "Hepatitis"

Abstract Number: 2454 • 2018 ACR/ARHP Annual Meeting
Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib
Yukitomo Urata, Rheumatology, Tsugaru General Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan
Background/Purpose: Although the increase in the incidence of Herpes Zoster by tofacitinib(TOF) in rheumatoid arthritis (RA) is well known, the reactivation rate of other viruses…
Abstract Number: 369 • 2017 ACR/ARHP Annual Meeting
Hepatitis A Virus Vaccination in Juvenile-Onset Systemic Lupus Erythematosus
Sevinc Mertoglu¹, Sezgin Sahin¹, Omer Faruk Beser², Amra Adrovic¹, Kenan Barut¹, Pelin Yuksel³, Soner Sazak⁴, Bekir Kocazeybek⁵ and Ozgur Kasapcopur¹, ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Pediatric Gastroenterology, Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Turkey, ³Microbiology, Istanbul University, Cerrahpasa Medical School, Department of Microbiology, Istanbul, Turkey, ⁴Pediatrics, Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical School, Department of Microbiology, Istanbul, Turkey
Background/Purpose: Various infections play significant roles in flares of systemic lupus erythematosus (SLE). Hepatitis A virus is one of these infectious agents that has high…
Abstract Number: 384 • 2017 ACR/ARHP Annual Meeting
Protection Against Hepatitis B in Immunocompromised Pediatric Rheumatology and Gastroenterology Patients
Najla Aljaberi¹, Emily A. Smitherman², Enas Ghulam³, Allen Watts², Dana MH Dykes⁴ and Jennifer L. Huggins⁵, ¹Pediatric rheumatology, Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Environmental health and biostatistics, Department of Environmental Health, University of Cincinnati, Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Hepatitis B infection remains a significant public health challenge, particularly for patients on chronic immunosuppressive therapy, due to a considerable mortality risk associated with…
Abstract Number: 385 • 2017 ACR/ARHP Annual Meeting
Reliable Implementation of a Hepatitis B Serology Screening and Vaccination Process for Immunocompromised Pediatric Rheumatology Patients
Emily A. Smitherman¹, Adam Furnier², Allen Watts¹, Sandra Kramer¹, Elizabeth Joy Baker¹, Dana MH Dykes³, Rebecca Brady⁴ and Jennifer L. Huggins⁵, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Vaccine-preventable infections, including reactivation of hepatitis B virus, are a leading cause of morbidity and mortality in immunocompromised patients. Guidelines recommend that all immunosuppressed…
Abstract Number: 1099 • 2017 ACR/ARHP Annual Meeting
Hepatitis B Reactivation in Rheumatologic Patients
Yassir Daghistani¹, Fergus To², Patrick Doyle^3,4, Hin Hin Ko⁵, Mel Krajden^3,4, Jason Kur², Alnoor Ramji⁶, Kam Shojania², Edward Tam⁵, John Wade², Eric Yoshida⁵, Graham Reid², Siegfried Erb⁵ and Mollie Carruthers², ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴BC Centre for Disease Control, Vancouver, BC, Canada, ⁵Gastroenterology, University of British Columbia, Vancouver, BC, Canada, ⁶Gatroenterology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The widespread usage of biologic disease modifying anti-rheumatic drugs (bDMARDs) in rheumatology has increased the risk of hepatitis B virus (HBV) re-activation. The prevalence…
Abstract Number: 2385 • 2017 ACR/ARHP Annual Meeting
High Incidence of Hepatitis Related to HBV Reactivation in Rheumatoid Arthritis Patients with Resolved Hepatitis B Infection during Rituximab Treatment
Ming-Han Chen¹, Yen-Po Tsao², Yi-Hsiang Huang³, Chung-Tei Chou⁴ and Chang Youh Tsai², ¹Division of Allergy- Immunology- Rheumatology, Department of Medicine, Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ²Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ³Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
AbstractBackground/Purpose: Rituximab-based chemotherapy can induce hepatitis B virus (HBV) reactivation (HBVr) in patients with hematological malignancies who have been exposed to HBV infection. However, informative…
Abstract Number: 10 • 2016 ACR/ARHP Annual Meeting
The Utility of Screening for Infectious Diseases in Recipients of Anti-TNF-α Therapy
Kristal Choi¹, Lester Mertz², Russell Heigh³, James Yiannias⁴ and Janis Blair⁵, ¹Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, ²Rheumatology, Mayo Clinic Arizona, Scottsdale, AZ, ³Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ, ⁴Dermatology, Mayo Clinic Arizona, Scottsdale, AZ, ⁵Infectious Diseases, Mayo Clinic Arizona, Scottsdale, AZ
The Utility of Screening for Infectious Diseases in Recipients of Anti-TNF-α Therapy Choi, Kristal, Mertz, Lester, Heigh, Russell, Yiannias, James, Blair, Janis Background/Purpose: Tumor…
Abstract Number: 431 • 2016 ACR/ARHP Annual Meeting
Wide Variations in Hepatitis B Screening Practices for Patients Receiving Rituximab
Gabriela Schmajuk¹, Chris Tonner², Laura Trupin³, Jing Li⁴ and Jinoos Yazdany³, ¹San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Hepatitis B reactivation in the setting of rituximab use is a potentially fatal but preventable event. The rate of hepatitis B screening in patients…
Abstract Number: 433 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Marin de Jong^1,2, Danielle Roosen¹, Andy Peters¹, Valerie Verstraeten³, Marieke Pierik¹ and A. van Tubergen⁴, ¹Department of Internal Medicine, division of Gastroenterology, Maastricht University Medical Centre, Maastricht, Netherlands, ²NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands, ³Department of Dermatology, Maastricht University Medical Centre, Maastricht, Netherlands, ⁴Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Biologicals are a powerful treatment option for moderate to severe immune-mediated inflammatory diseases (IMID). Since biologicals modulate the immune system, the risk for reactivation…
Abstract Number: 502 • 2015 ACR/ARHP Annual Meeting
Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
Jennifer Barnard¹, Nida Meednu², Kelly Callahan¹, Karen Boyle³, Lynette Keyes-Elstein³, Beverly Welch⁴, Ellen Goldmuntz⁵ and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵DAIT, NIAID/NIH, Bethesda, MD
Background/Purpose: TNF is a key pro-inflammatory cytokine in normal immune responses and pathologically in the rheumatoid arthritis (RA) synovium, thus representing a key treatment target…
Abstract Number: 1358 • 2015 ACR/ARHP Annual Meeting
Detection of a Unique Viral Infection in Salivary Glands of Sjögren’s Syndrome Patients and Viral-Mediated Recapitulation of Disease in Vivo
Melodie Weller¹, Matthew Gardner¹, Zoe Bogus¹, Michael Smith¹, Elisa Astorri², Drew Michael¹, Changyu Zheng¹, Peter Burbelo³, Paul A. Wilson⁴, Zhennan Lai¹, Bill Swaim¹, Beverly Handelman¹, Sandra Afione¹, Michele Bombardieri² and John A. Chiorini¹, ¹Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ³Clinical Dental Research Core, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ⁴National Intramural Database, Division of Enterprise and Custom Applications, Center for Information Technology, National Institutes of Health, Bethesda, MD
Background/Purpose: A viral infection is thought to be one of the triggers in the development of primary Sjögren’s syndrome (pSS). Multiple studies have shown stimulation…
Abstract Number: 1576 • 2015 ACR/ARHP Annual Meeting
Effect of Conventional Synthetic and Biological Disease Modifying Anti-Rheumatic Drugs on the Immunogenicity of Hepatitis B Vaccine in Patients with Rheumatoid Arthritis
Samanan Intongkam¹, Rattapol Pakchotanon², Sumapa Chaiamnuay², Paijit Asavatanabodee² and Pongthorn Narongroeknawin², ¹Internal medicine, Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand
Background/Purpose: Immunogenicity of pneumococcal and influenza vaccine in patients with rheumatoid arthritis (RA) have been assessed in many studies. However, the humoral immune response of…
Abstract Number: 2164 • 2014 ACR/ARHP Annual Meeting
Self-Phospholipids Regulate Inflammation Via Activation of CD1d-Restricted T-cells and Induction of ‘anti-inflammatory’ Myeloid-Derived Suppressor Cells (MDSC)
Ram Raj Singh^1,2,3,4, Cynthia Tran¹, Priti Prasad¹, Jing Wang⁵, Dirk Zajonc⁵ and Ramesh Halder¹, ¹Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, ²Interdepartmental Program in Molecular Toxicology, UCLA, Los Angeles, CA, ³Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, ⁴Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, ⁵La Jolla Institute of Allergy and Immunology, La Jolla, CA
Background/Purpose Self-lipids play an increasingly appreciated role in immunity and inflammation. Lipid antigens are presented by CD1d and CD1a-d molecules in mouse and human, respectively,…
Abstract Number: 484 • 2014 ACR/ARHP Annual Meeting
Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis after Anti-TNF Therapy
Seung Min Jung¹, Hong Ki Min¹, Jung Hee Koh¹, Jin Young Kang¹, Jennifer Lee¹, Seung-Ki Kwok², Ji Hyeon Ju¹, Hyeok-Jae Ko³, Kyung-Su Park⁴, Ho-Youn Kim¹ and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, St. Mary’s hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea, ⁴Internal Medicine, St. Vincent Hospital, SuWon Gyeonggi-do, South Korea
Background/Purpose: Anti-TNF therapy was known to increase the risk of certain infection. There are only limited data about the reactivation of hepatitis B virus (HBV)…
Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].